BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that new efficacy and safety data from the first ...

Advancement of the study into the Phase 2 expansion follows the successful completion of the Phase 1 dose escalation portion of the trial, where 1.0 mg of tivozanib was administered for 21 days ...

AVEO Oncology (formerly known as AVEO Pharmaceuticals) announced the presentation of results from the phase 1b portion of the phase 1b/2 DEDUCTIVE clinical trial of tivozanib (Fotivda), AVEO’s ...

Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations. This is an ASCO Meeting Abstract from the 2022 ASCO ...

ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.

We often express our thoughts in words to communicate ideas, present arguments or make decisions. But what format and structure do these thoughts take in the brain? In the fields of philosophy, ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Large language models (LLMs) have shown impressive performance on various ...

BOSTON--(BUSINESS WIRE)-- AVEO Oncology (NASDAQ: AVEO) today announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA® (tivozanib), the Company’s once-daily, potent and selective next ...

AVEO Oncology AVEO today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA ®), AVEO's vascular endothelial growth factor ...